Human Tetanus Immunoglobulin Market Trends, Industry | 2031

Report Description

Market Outlook:

The Global Human Tetanus Immunoglobulin Market was estimated at USD 615.92 Million in 2022 and is anticipated to reach USD 957.49 Million by 2031, expanding at a CAGR of 5.2% during the forecast period.

Tetanus immunoglobulin (TIG) is recommended for those who have tetanus. TIG only helps to remove unbound tetanus toxin. TIG contains large amounts of antibodies derived from donated human blood. Tetanus Immunoglobulin, used intravenously, is made from human plasma that is the liquid component of blood. Tetanus immunoglobulin is a solution comprising antibodies that provide immediate protection against tetanus. Tetanus Immunoglobulin (TIG) is recommended for tetanus treatment and prophylaxis against tetanus, following injury in patients with insufficient or uncertain tetanus immunization.

Get Free Sample Report

Macro-economic Factors

Global Population

The global population is growing at an alarming rate, putting a major strain on healthcare, increasing susceptibility to  vulnerable groups of people. Overpopulation reduces quality of life and impacts other social and environmental issues. Overpopulation causes malnutrition, pollution, congested living conditions, and a lack of healthcare services, increase the risk of infectious diseases in a community.

Immunization Coverage

According to the World Health Organization (WHO), tetanus is an acute infectious disease caused by spores of the bacterium clostridium tetani. Maternal and neonatal tetanus is still a public health concern in approximately 12 countries, major in Africa and Asia. In 2022, 14.3 million infants did not receive an initial dose of the DTP vaccine, pointing to a lack of access to preventive vaccines (immunization and other health services) lead to increase population of unvaccinated and partially vaccinated people.

Market Dynamics

Major Driver- Increasing Number of Injuries Across the Globe

Increasing incidences of injuries such as chronic wound & infectious injuries, road traffic accidents, sports injuries, and burn injuries are expected to boost the market during the forecast period. For instance, according to a data from World Health Organization (WHO), every year more than 1.19 million people decease as a result of road traffic crashes. These injuries are the primary cause of death for children and young adults aged five to 29 years. The incidence of sports injuries drive the market as well.

For instance, according to a finding, 6.2 million people annually seek hospital treatment in European Union due to sports injuries, and 7% of them, which are 402,000 cases, have to be admitted in hospitals for further treatment.

Major Driver- Occurrence of Tetanus Cases in Developing Countries

Occurrence of tetanus cases in developing nations such as India, Pakistan, Indonesia, Nigeria, Somalia, Kenya, and South Sudan are expected to increase the demand for human tetanus toxoid or vaccines during the forecast period. Moreover, the risk of tetanus infections in immunocompromised patients such as hematologic malignancies, solid-organ transplant, HIV infection, and cancer is rising in these countries. From 1990 to 2019, the incident cases of tetanus decreased by 88% worldwide, from 615,728 to 73,662.

The WHO estimates a growing burden of tetanus among adult men, particularly in countries that do not provide tetanus booster shots. For instance, Sub-Saharan Africa has the high rate of non-neonatal tetanus cases per million population, with men accounting for 71% of hospitalized tetanus patients.

Existing Restraint- High Cost of Tetanus Immunoglobulin Injection

High cost of tetanus immunoglobulin injections is expected to hinder the market during the forecast period. The cost is high, as the manufacturing process is complex, due to the high possibility of contamination. The fluctuating cost of tetanus immunoglobulin injections in different countries is a significant factor in determining their accessibility and affordability for patients.

The high cost of tetanus immunoglobulin injections is anticipated to limit the demand for the product, particularly in low and middle-income countries, where access to healthcare is limited. Thus, patients seek out different treatments or reduce utilization of these injections. Moreover, balancing affordability with quality care is crucial for the sustained market growth.

Emerging Opportunity- Growing Healthcare Infrastructure and Expenditure

Health spending is defined as the final consumption of healthcare goods and services such as current health expenditure. It includes both personal health care such as curative care, rehabilitative care, long-term care, ancillary services, & medical goods and collective services such as prevention & public health services as well as health administration. However, it excludes investment spending.

Health expenditure includes all expenditures for the provision of health services, family planning activities, nutrition activities, and emergency aid designated for health. Global healthcare spending in 2022 was around USD 10,059 Bn. Across the European Union, healthcare spending per capita growth between 2019 and 2022 accelerated to 3.3 %, with a peak in 2021. The top spender across the globe on healthcare is the US with 16.6% spending of its GDP in 2022. It was followed by Germany, which spends 12.7% of its GDP on healthcare, and France, which spends the equivalent of 12.1% of its GDP.

Scope of the Report  

The report on the Global Human Tetanus Immunoglobulin Market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Segmental Outlook

Based on dose, the human tetanus immunoglobulin market is segmented into 250 IU and 500 IU. The 500 IU segment is expected to hold a substantial share of the market during the forecast period, as it provides immediate and short-term protection against the bacteria that cause tetanus or lockjaw. Human tetanus immunoglobulin 500 IU is recommended for treatment of tetanus, following injury in patients whose tetanus immunization is incomplete or uncertain.

Get Free Sample Report

Based on age group, the human tetanus immunoglobulin market is segmented into adults and children. The adult’s segment is projected to account for a significant share of the market during the forecast period, due to the rise in prevalence rate of the tetanus infections among adults. For instance, in 2021, 26 Europe/European Economic Area (EU/EEA) countries reported 50 tetanus cases, 10 of which (20%) were classified as confirmed and 40 (80%) as probable.

Get Free Sample Report

Based on end use, the human tetanus immunoglobulin market is segmented into hospitals, clinics, and vaccination centers. The hospital segment is projected to account for a significant share during the forecast period, as hospitals provide a wide range of medical services to patients, including treatment for tetanus infections.

Get Free Sample Report

Based on sales channel, the human tetanus immunoglobulin market is segmented into retail pharmacy, hospital pharmacy, and online pharmacy. The retail pharmacy segment is projected to expand at a significant CAGR during the forecast period. The retail pharmacy is expected to register increased sales in the coming years, owing to the growing population and affordability of medicines in retail pharmacies.

Get Free Sample Report

Regional Outlook

On the basis of region, the global Human Tetanus Immunoglobulin market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa (MEA).

The market in North America accounted for significant market share owing to rising number of injuries by road accidents. For instance, according to a CNBC report, 42,915 people died in motor vehicle traffic crashes in 2021, which is a 10.5% increase from 2020. The presence of robust healthcare infrastructure is anticipated to increase the demand for human tetanus immunoglobulin in North America during the forecast period.

The market in Asia Pacific is projected to expand at a CAGR of 9.5% during the forecast period, owing to the growing awareness regarding immunization programs in developing nations of such as India and Indonesia. The overall success rate of tetanus treatment in China has dramatically improved, but the prevention and control of non-neonatal tetanus is still challenging.

Get Free Sample Report

Market Key Developments

• In December 2022, Kedrion Holding S.p.A. announced the acquisition of the Czech companies UNICAplasma sro and UNICAplasma Morava sro, which operate five plasma collection centers in the Czech Republic.

• In October 2022, CSL Limited announced the company has entered into a Strategic Option and License Agreement with Arizona-based Translational Sciences for their enhanced thrombus dissolving drug candidate, TS23.

• In September 2022, Grifols, S.A announced it had signed a pioneering long-term agreement with Canadian Blood Services, Canada’s national blood authority, to greatly increase the country’s self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.

• In February 2022, Grifols, S.A. announced a collaboration with Endpoint Health, Inc., a precision-medicine therapeutics company dedicated to addressing urgent needs in immune-driven critical care, to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis.

Key Benefits for Industry Participants & Stakeholders

• In-depth Analysis of the Global Human Tetanus Immunoglobulin Market

• Historical, Current, and Projected Market Size in terms of Value

• Potential & Niche Segments and Regions Exhibiting Promising Growth Covered

• Industry Drivers, Restraints, and Opportunities Covered in the Study

• Recent Industry Trends and Developments

• Competitive Landscape & Strategies of Key Players

• Neutral Perspective on Global Human Tetanus Immunoglobulin Market performance